OHR Pharmaceutical Inc (NASDAQ:OHRP) saw an uptick in trading volume on Wednesday . 11,344,013 shares were traded during mid-day trading, an increase of 37% from the previous session’s volume of 8,281,882 shares.The stock last traded at $0.37 and had previously closed at $0.32.
OHRP has been the subject of several recent research reports. ValuEngine downgraded OHR Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, January 5th. Roth Capital downgraded OHR Pharmaceutical from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Friday, January 5th. Finally, Zacks Investment Research downgraded OHR Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, October 26th.
The stock has a market cap of $19.58, a price-to-earnings ratio of -0.61 and a beta of 0.48.
A number of hedge funds and other institutional investors have recently made changes to their positions in OHRP. Wedbush Securities Inc. acquired a new stake in shares of OHR Pharmaceutical during the third quarter valued at about $311,000. Garrison Bradford & Associates Inc. grew its stake in shares of OHR Pharmaceutical by 482.4% during the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 412,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of OHR Pharmaceutical by 0.7% during the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after acquiring an additional 5,481 shares in the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.
WARNING: “OHR Pharmaceutical (OHRP) Sees Strong Trading Volume” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.themarketsdaily.com/2018/01/19/ohr-pharmaceutical-ohrp-sees-strong-trading-volume.html.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.